Rejected at 5:41 p.m. Mar, 10, 2024 ] by thomas.holmes
Author: robhornberger
Related Note: 1475803205680
Rationale for change

Spironolactone is an aldosterone receptor antagonist with antiandrogenic properties that is considered one of the most effective second-line treatment options for patients with hirsutism. Spironolactone can be used in patients with hirsutism that have shown minimal to no response after treatment with COCs for at least 6 months or in those who cannot take COCs.
Source: AMBOSS - https://next.amboss.com/us/questions/hQQ20cDDh2/20

Rejection reason

already covered in nid:1475803200843

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Low/HighYield::3-HighYield-temporary #AK_Step2_v12::#SketchyOBGYN::06_Reproductive_Endocrinology_&_Infertility::01_Reproductive_Endocrinology::04_Hirsutism_&_Virilization_DDx #AK_Step2_v12::#AMBOSS::oq00zS #AK_Step1_v12::#Pixorize::03_Pharmacology::18_Renal_Pharm::02_Aldosterone_Receptor_Blockers_(Spironolactone/Eplerenone) #AK_Step1_v12::#Textbooks::#Marks_Biochemistry::32_Cholesterol_Absorption_Synthesis_Metabolism_and_Fate #AK_Step1_v12::^Systems::Renal::Pharmacology #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#OME::Clinical::Intern_Bootcamp #AK_Step1_v12::#Bootcamp::Reproduction::06_Pharmacology::04_Antiandrogens #AK_Step1_v12::#FirstAid::15_Repro::05_Pharm::13_Antiandrogens::*Spironolactone #AK_Step1_v12::#AMBOSS::C_0qqi #AK_Step1_v12::#Bootcamp::Nephrology::15_Renal_Pharmacology::05_Potassium-Sparing_Diuretics #AK_Step1_v12::#Physeo::09_Pharm::06_Renal::05_Potassium-sparing_Diuretics #AK_Step1_v12::#Physeo::09_Pharm::12_Reproductive::10_Antiandrogens #AK_Step1_v12::#B&B::09_Endocrinology::04_Repro::07_Secondary_Amenorrhea::Extra #AK_Step2_v12::#SketchyOBGYN::05_Benign_Gynecology_&_Urogynecology::02_Abnormal_Uterine_Bleeding_&_Pelvic_Pain::03_Abnormal_Uterine_Bleeding_DDx #AK_Step1_v12::#AMBOSS::N6a-Ol #AK_Step1_v12::#AMBOSS::Xra9fN #AK_Step1_v12::#FirstAid::14_Renal::05_Pharm::06_Potassium-sparing_diuretics #AK_Step1_v12::#SketchyPharm::02_Cardio_&_Renal::02_Diuretics::04_K+_sparing_diuretics #AK_Step1_v12::#Textbooks::#Golan_Pharmacology::21_Pharmacology_Of_Volume_Regulation #AK_Step1_v12::#UWorld::Step::2095 #AK_Step2_v12::#AMBOSS::38aSmm #AK_Step1_v12::#Textbooks::#Golan_Pharmacology::30_Pharmacology_Of_Reproduction #AK_Step2_v12::#B&B::11_Obstetrics_and_Gynecology::02_Gynecology::04_Secondary_Amenorrhea::Extra #PANCE::EOR::WOMENS_HEALTH #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::11_Potassium_Sparing_Diuretics_(MOA,_Indications,_AR,_CI) #AK_Step2_v12::#AMBOSS::8r0OQh #AK_Step1_v12::#AMBOSS::EQa8B4 #PANCE::REPRODUCTIVE::ovarian_disorders #AK_Other::Only_Step_1&2_Overlap #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology